Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder of unknown aetiology. Progressive motor weakness and bulbar dysfunction lead to premature death, usually from respiratory failure. To date, riluzole is the only disease-modifying drug approved for the treatment of ALS, but this has only a minor impact on the clinical outcome. The clinical development of new drugs for ALS is entirely dependent on the understanding of the aetiology and pathophysiology of the disease, which is still far from being fully elucidated. ALS is a multisystem disorder and can be viewed as the consequence of a complex neurodegenerative process involving neuron-glia interactions. Excitotoxicity, oxidative stress, mitochondrial dysfunction, cytoskeletal defects and apoptosis are all putative mechanisms which seem to operate in ALS and might be amenable of pharmacological intervention. Since the pathogenesis of ALS seems to involve multiple factors, future treatments may target different molecular pathways by a combined multi-drug therapy.
Keywords: als, neuroprotection, clinical trials, excitotoxicity, oxidative stress, apoptosis
Current Neuropharmacology
Title: Possible Neuroprotective Strategies in ALS
Volume: 2 Issue: 3
Author(s): Simone Beretta, Laura Brighina and Carlo Ferrarese
Affiliation:
Keywords: als, neuroprotection, clinical trials, excitotoxicity, oxidative stress, apoptosis
Abstract: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder of unknown aetiology. Progressive motor weakness and bulbar dysfunction lead to premature death, usually from respiratory failure. To date, riluzole is the only disease-modifying drug approved for the treatment of ALS, but this has only a minor impact on the clinical outcome. The clinical development of new drugs for ALS is entirely dependent on the understanding of the aetiology and pathophysiology of the disease, which is still far from being fully elucidated. ALS is a multisystem disorder and can be viewed as the consequence of a complex neurodegenerative process involving neuron-glia interactions. Excitotoxicity, oxidative stress, mitochondrial dysfunction, cytoskeletal defects and apoptosis are all putative mechanisms which seem to operate in ALS and might be amenable of pharmacological intervention. Since the pathogenesis of ALS seems to involve multiple factors, future treatments may target different molecular pathways by a combined multi-drug therapy.
Export Options
About this article
Cite this article as:
Beretta Simone, Brighina Laura and Ferrarese Carlo, Possible Neuroprotective Strategies in ALS, Current Neuropharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570159043359684
DOI https://dx.doi.org/10.2174/1570159043359684 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Preparation of Hymenialdisine, Analogues and Their Evaluation as Kinase Inhibitors
Current Medicinal Chemistry Glutamate Receptors in Human Caudate Nucleus in Normal Aging and Alzheimer’s Disease
Current Alzheimer Research Arachidonic Acid Metabolites in Neurologic Disorders
CNS & Neurological Disorders - Drug Targets Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Effects of Therapeutic Hypothermia on the Glial Proteome and Phenotype
Current Protein & Peptide Science Chondroitin Sulfate Glycosaminoglycans for CNS Homeostasis-Implications for Material Design
Current Medicinal Chemistry Amyotrophic Lateral Sclerosis and Oxidative Stress: A Double-Blind Therapeutic Trial After Curcumin Supplementation
CNS & Neurological Disorders - Drug Targets Sirtuins: Nodes Connecting Aging, Metabolism and Tumorigenesis
Current Pharmaceutical Design Patent Selections
Recent Patents on Food, Nutrition & Agriculture Editorial: [Hot Topic: Therapeutic Antioxidants for Neurodegenerative Disease]
Recent Patents on CNS Drug Discovery (Discontinued) Emerging Methods for Structural Analysis of Protein Aggregation
Protein & Peptide Letters Programmed Cell Death Mechanisms in Neurological Disease
Current Molecular Medicine Neuron Protection as a Therapeutic Target in Acute Ischemic Stroke
Current Topics in Medicinal Chemistry Syntheses, Transformations and Pharmaceutical Applications of Kynurenic Acid Derivatives
Current Medicinal Chemistry Cannabinoids: Occurrence and Medicinal Chemistry
Current Medicinal Chemistry Magnetic Materials for the Selective Analysis of Peptide and Protein Biomarkers
Current Medicinal Chemistry Gene Therapy and Cell Reprogramming For the Aging Brain: Achievements and Promise
Current Gene Therapy A Novel Relationship for Schizophrenia, Bipolar and Major Depressive Disorder Part 6: A Hint from Chromosome 6 High Density Association Screen
Current Molecular Medicine Alzheimer's disease: Targeting the Cholinergic System
Current Neuropharmacology Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry